GB:0ABW Stock Latest News
Company AnnouncementsEgetis Therapeutics Launches First FDA-Approved EMCITATE Therapy for MCT8 Deficiency in U.S.6d ago
Company AnnouncementsEgetis Therapeutics Sets Nomination Committee for 2027 AGM1w ago
Company AnnouncementsEgetis bolsters tiratricol case with largest RTH-beta cohort study2w ago
Company AnnouncementsEgetis Therapeutics Adjusts Share Composition After Employee Stock Option Exercise1M ago
Company AnnouncementsEgetis Wins First U.S. FDA Approval for MCT8 Deficiency Therapy EMCITATE1M ago
Company AnnouncementsEgetis to Present New Emcitate Data at Major European Endocrinology Meetings1M ago
Company AnnouncementsEgetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision2M ago
Pre-EarningsIs P0F a Buy, Before Earnings?2M ago- Company AnnouncementsEgetis sets Q2 2026 results date as Emcitate nears key FDA decision2M ago
Company AnnouncementsEgetis Backs National Lifetime Re-Air of MCT8 Deficiency Awareness Episode4M agoCompany AnnouncementsEgetis Converts Class C Shares After Option Exercise, Boosting Voting Rights5M ago
Company AnnouncementsEgetis highlights MCT8 healthcare costs as Emcitate nears key U.S. review5M ago
- Company AnnouncementsEgetis Executives Exercise Stock Options and Sell Shares for Tax and Personal Reasons5M ago
Company AnnouncementsEgetis Targets Global Specialist Community With 2026 Conference Push5M ago
Company AnnouncementsEgetis Gains Key U.S. Patent Protection for Emcitate in MCT8 Deficiency6M ago- Company AnnouncementsEgetis Uses Pediatric Endocrine Meeting to Build Momentum for Emcitate6M ago
Company AnnouncementsEgetis boosts share capital as it advances rare-disease drug portfolio6M ago
